![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Sertraline hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2015-139 - Rev 01
This Chemical Type CEP, issued on July 09, 2018, remains in force until March 14, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 1705 associated with this CEP further emphasizes